- Home
- FOLD
as 03-28-2025 4:00pm EST
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 2.9B | IPO Year: | 2007 |
| Target Price: | $17.00 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.36 - $12.65 | Next Earning Date: | 05-08-2025 |
| Revenue: | $528,294,999 | Revenue Growth: | 32.29% |
| Revenue Growth (this year): | 21.91% | Revenue Growth (next year): | 22.22% |
Stock Insider Trading Activity of Amicus Therapeutics Inc. (FOLD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Campbell Bradley L | FOLD | President and CEO | Feb 19 '25 | Sell | $10.00 | 400 | $4,000.00 | 1,150,657 |
Latest Amicus Therapeutics Inc. News
FOLD Breaking Stock News: Dive into FOLD Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue?
Zacks
7 days ago
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Insider Monkey
11 days ago
Is Amicus Therapeutics Inc. (FOLD) the Best Nasdaq Stock Under $20 to Buy Now?
Insider Monkey
16 days ago
Amicus Therapeutics, Inc. (FOLD): Among the Stocks Under $10 With High Upside Potential
Simply Wall St.
a month ago
US High Growth Tech Stocks With Strong Potential
GlobeNewswire
a month ago
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
Insider Monkey
a month ago
Why Amicus Therapeutics, Inc. (FOLD) is the Most Oversold Pharma Stock to Buy According to Analysts
Zacks
a month ago
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
Compare FOLD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FOLD Amicus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.